<DOC>
	<DOCNO>NCT01691742</DOCNO>
	<brief_summary>A . Purpose To compare MiraLAX versus placebo prevent constipation immediate postoperative period follow pelvic reconstructive surgery woman take routine docusate sodium . B . Objectives 1 . Specific Aims Specific Aim 1 : To compare time first bowel movement ( BM ) MiraLAX versus placebo woman receive routine docusate sodium pelvic reconstructive surgery . Specific Aim 2 : To compare patient report outcomes BM quality associate gastrointestinal ( GI ) symptoms MiraLAX versus placebo use Bristol stool scale validate Patient Assessment Constipation Symptom Questionnaire ( PAC-SYM ) woman receive routine docusate sodium pelvic reconstructive surgery . Specific Aim 3 : To evaluate GI-related quality life MiraLAX versus placebo utilize validated Patient Assessment Constipation Quality-of-Life Questionnaire ( PAC-QOL ) woman receive routine docusate sodium pelvic reconstructive surgery . 2 . Hypotheses The investigator hypothesize MiraLAX optimally prevent constipation follow pelvic reconstructive surgery decreasing time first BM , decrease GI symptom associate constipation , increase measure GI-related quality life , minimize bothersome side effect associate stimulant laxative .</brief_summary>
	<brief_title>MiraLAX Versus Placebo Prevent Constipation Following Urogynecologic Surgery</brief_title>
	<detailed_description>This randomized double-blind placebo-controlled clinical trial MiraLAX versus placebo woman undergo pelvic reconstructive surgery receive routine docusate sodium . Subjects screen eligibility preoperative visit enrol , randomize receive MiraLAX placebo start postoperative day ( POD ) 1 continue POD 5 . Subjects instructed stop take medication experience diarrhea . Subjects arm instruct take milk magnesia rescue laxative experience BM morning POD 6 . All subject provide 30 day supply docusate sodium instruct begin medication POD 1 .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Laxatives</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<mesh_term>Cathartics</mesh_term>
	<mesh_term>Bismuth subsalicylate</mesh_term>
	<mesh_term>Magnesium Hydroxide</mesh_term>
	<criteria>Englishspeaking female patient &gt; 18 year age Not pregnant ( patient childbearing potential serum pregnancy test do preoperatively part surgical planning ) Undergoing surgery pelvic organ prolapse stress urinary incontinence Recruited Duke University Division Urogynecology Allergy/hypersensitivity study medication Cardiac renal disease Takes chronic daily laxative Excluded unable complete least 5 day 7 day baseline bowel diary Excluded mesh resection Interstim procedure Excluded concurrent surgery include anal sphincteroplasty rectovaginal fistula repair</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Postoperative constipation</keyword>
	<keyword>Urogynecologic Surgery</keyword>
	<keyword>MiraLax</keyword>
	<keyword>Docusate Sodium</keyword>
</DOC>